A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC)
Latest Information Update: 06 Dec 2024
At a glance
- Drugs SHR 2005 (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Sponsors Shanghai Hengrui Pharmaceutical
- 03 Dec 2024 Planned number of patients changed from 150 to 170.
- 27 Dec 2023 Status changed from not yet recruiting to recruiting.
- 08 Nov 2023 New trial record